Immune checkpoint inhibitors, especially anti-PD-1 or anti-PD-L1 antibodies, aim to disrupt PD-1/PD-L1 signaling in the TME thereby reversing T cell suppression and enhancing anti-tumor immunity [33,112]. Here, CD274 is linked to neoplasm.